The COBRRA randomized trial that compared direct oral anticoagulants (DOACs) for acute venous thromboembolism (VTE), and ...
Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism, which have incidence rates of between 1 and 2 cases per 1000 people for the first episode.1,2 Strong, provoking risk ...
In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results